Transcription of JCOG1109 - トップページ：日本臨床腫瘍研究 ...
{{id}} {{{paragraph}}}
Example: marketing
JCOG1109 - トップページ：日本臨床腫瘍研究 ...
Japan Clinical Oncology Group .. 29-A-3. JCOG . 17ck0106188h0003.. JCOG1109 . IB/II/III T4 CF / DCF /. CF-RT III ver. A randomized controlled phase III comparing CF versus DCF versus CF-RT. as neoadjuvant treatment for locally advanced esophageal cancer RCT of Neoadjuvant therapy for Esophageal cancer by Triple arm NExT study .. / .. 104-0045 5-1-1. 9 17 JCOG PC1109 . 2012 11 1 JCOG . 2013 10 11 ver. JCOG 10 21 . 2014 6 2 ver. JCOG 6 5 . 2015 6 8 ver. JCOG 6 9 . 2017 11 2 ver. JCOG 11 9 . JCOG 1109 ver. 0.. cStage IB/II/III T4 5-FU cddp CF . 3 5-FU cddp Docetaxel DCF 5-FU cddp . Gy CF-RT III . Primary endpoint . Secondary endpoints .. 1) .. 2) UICC-TNM 7 . EMR Te . EMR .. 3) TNM UICC-TNM 7 cStage IB II T4 III . 4) 20 75 . 5) Performance status PS ECOG 0 1 PS.
（T4 を除く）患者を対象に、標準治療である術前5-FU＋CDDP（CF）療法に対す る、3 剤併用術前化学療法（5-FU＋CDDP＋Docetaxel（DCF）療法）と、術前化学放射線療法（5-FU＋CDDP＋
Loading..
Tags:
Information
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document: